Turning on the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Valsartan, a medication used in the treatment of high blood pressure and congestive heart failure, increases the expression of tumor suppressors genes, such as BigH3, TIPE2, PTEN, PDCD4, INK4a, BTG2, TA-p73/p63, TPM1, TIMP3, CCM1/KRIT1 and others, induces regression of p53-mutated human tumors, via down regulation of its target gene, 20/April/2017, 2.42 pm
Bonding your way to live longer: Oxytocin-based anti-ageing and Lifespan extension therapy: Oxytocin (also known as compassion/goodness/bonding hormone), a peptide hormone and neuropeptide known to play a role in empathy, generosity, childbirth and so on, increases CHIP levels, increases monoubiquitylation of insulin receptor (INSR), decreases INSR protein levels and enhances lifespan via down regulation of its target gene, 20/April/2018, 12.38 pm
April 20, 2018
Olive oil-based therapy for Deafness: A therapeutic mix encompassing Hydroxytyrosol, Cholecalciferol, Ajoene and DIM (HTCAD) increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration, improves hearing loss via up regulation of its target genes, 20/April/2018, 2.50 pm
April 20, 2018From Significance of the study to Public health relevance:
Given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53 pathway is altered in about 80% of tumors.; (3) our understanding is incomplete in terms of molecular targets and the oncogenic/malignant pathways involved in mutant p53-overexpressing tumors; (4) cancer causes the highest economic loss compared to all the known causes of death worldwide; and (5) cancer causes the considerable economic loss worldwide, there is an urgent need to find: (i) a cheaper alternative to the existing expensive drugs; (ii) a side-effect-free natural product-based drug; and (iii) a way to effectively treat and stall metastatic progression and relapse of mutant p53-overexpressing human cancers.
From therapeutic strategy to Research Findings:
(i) Therapeutic strategy:
This study suggests a therapeutic strategy for stalling the progression of p53-deficient/deleted or mutant-p53 expressing metastatic cancers. By activating tumor suppressor p53’s unmutated “homologous protein such as TAp73/p63” in p53-deficient or mutant-p53 expressing metastatic cancer cells, one can stall their progression.
(ii) Research findings:
A number of studies suggests that the valsartan functions as an anticancer agent. However, the mechanism of action is far from clear.
This study suggests, for the first time, that valsartan, by decreasing the expression of its target gene, it may increase the expression of tumor suppressors genes, such as BigH3, TIPE2, PTEN, PDCD4, INK4a, BTG2, TAp73α, TIMP3, CCM3/KRIT1 and others. Thereby, it may inhibit the migration and invasion of metastatic cancer cells expressing mutant-p53 (figure1).
Figure 1. Mechanistic insight into how valsartan functions as an anticancer/antimetastatic agent in mutant p53-expressing tumors. Valsartan, by activating tumor suppressor genes, such as BigH3, TIPE2, PTEN, PDCD4, INK4a, BTG2, TAp73α, TIMP3, CCM3/KRIT1 and others, in metastatic tumors, it may inhibit the progression of mutant-p53 expressing human cancers.
Therapeutic opportunity:
Given the ability of valsartan to induce the expression of a number of tumor suppressor genes, pharmacological formulations encompassing “valsartan or its analogues, either alone or in combination with other anticancer drugs,“ may be used to inhibit the progression of p53-mutated invasive metastatic tumors.
Taken together, this study suggests that oncologists may consider treating terminally ill metastatic cancer patients with valsartan, as it may stall the progression of advanced metastatic cancers.
Details of the research findings:
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Amount: $300#
Undisclosed mechanistic information: How valsartan increases the expression of tumor suppressor genes, such as BigH3, TIPE2, PTEN, PDCD4, INK4a, BTG2, TAp73α, TIMP3, CCM3/KRIT1 and others, in mutant p53 expressing cancer cells?
For purchase and payment details, you may reach us at admin@genomediscovery.org
#Research cooperation
References:
Web: http://genomediscovery.org or http://newbioideas.com
Citation: Boominathan, L., Turning on the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Valsartan, a medication used in the treatment of high blood pressure and congestive heart failure, increases the expression of tumor suppressors genes, such as BigH3, TIPE2, PTEN, PDCD4, INK4a, BTG2, TA-p73/p63, TPM1, TIMP3, CCM1/KRIT1 and others, induces regression of p53-mutated human tumors, via down regulation of its target gene, 20/April/2017, 2.42 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at admin@genomediscovery.org
